As­traZeneca leans in­to GLP-1; Cuts loom­ing at Bay­er; Eli Lil­ly’s obe­si­ty ap­proval; End­points Slack in­ter­view with Matt Gline; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Both Bay­er and As­traZeneca took to their Q3 up­dates to un­veil some big moves, al­beit in some­what dif­fer­ent di­rec­tions, while our team al­so high­light­ed the most in­ter­est­ing nuggets out of oth­er com­pa­nies’ earn­ings calls. Don’t miss our Slack in­ter­view with Roivant’s Matt Gline and look in­to ear­ly da­ta on in vi­vo cell ther­a­py, too.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER